( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Open accessThe DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.
Abstract
Significance: Despite available medications for depression, currently approved antidepressants take months to exert therapeutic effects, and ∼30% of patients remain treatment resistant. In contrast, a single subanesthetic dose of ketamine exerts rapid (within hours) and sustained antidepressant actions. Preclinical studies indicate that the ketamine metabolite ( 2R , 6R )-hydroxynorketamine [( 2R , 6R )-HNK] is a rapid-acting antidepressant candidate with limited adverse effects compared with ketamine. Using behavioral, genetic, and pharmacological approaches and EEG measurements, we determined that the mechanism underlying antidepressant-relevant actions of ( 2R , 6R )-HNK converges with metabotropic glutamate receptor subtype 2 (mGlu 2 ) receptor signaling and identified high-frequency EEG oscillations as a marker associated with rapid antidepressant responses. Our data support the use of individually subtherapeutic doses of mGlu 2 receptor inhibitors with ketamine or ( 2R , 6R )-HNK in clinical trials for the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Administration of LY379628 before (2R,6R)-HNK also prevented the rescue of anhedonic-like behavior and shockinduced escape deficits.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [193]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“an mGluR2/3 agonistinduced hypothermic assay demonstrated that racemic ketamine and (2R,6R)-HNK prevented the increases in body temperature induced by an mGluR2/3 orthostatic agonist (LY379628), implicating mGluR2/3 antagonism in ketamine's antidepressant effects [193]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [193]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“These findings were not replicated with other NMDAR antagonists or with 6,6-d2-(R,S)-ketamine [193]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [193]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guide for the Care and Use of Laboratory Animals: Eighth Edition
(2011) · doi:10.17226/12910 · Cited by 16,199
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 1×
“A monoamine-targeting pharmacotherapies to treat depression, such as selective serotonin-reuptake inhibitors, are commonly used, more than 30% of severely depressed individuals remain treatment resistant (1).”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease
Niswender, C. M., & Conn, P. J. (2010) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.011008.145533 · Cited by 1,892
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 2×
“Although ketamine’s overall effect on gamma power is likely influenced by its actions to inhibit the NMDAR expressed on GABAergic interneurons (83, 94, 95), the results here suggest an explanation whereby (2R,6R)-HNK exerts its effects on gamma oscillations via a mechanism that does not involve NMDAR inhibition.”
BackgroundResultNMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609
Self-citationKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Self-citationHomayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 2×
“Although ketamine’s overall effect on gamma power is likely influenced by its actions to inhibit the NMDAR expressed on GABAergic interneurons (83, 94, 95), the results here suggest an explanation whereby (2R,6R)-HNK exerts its effects on gamma oscillations via a mechanism that does not involve NMDAR inhibition.”
BackgroundResultMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Mechanisms of ketamine action as an antidepressant
Zanos, P., & Gould, T. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.255 · Cited by 1,127 · cited 1×
“Antidepressant-relevant actions of ketamine and (2R,6R)HNK converge on a glutamate-associated enhancement of neuronal activity in mood-regulating synapses, which are proposed to both initiate and sustain their effects (13, 31, 32).”
BackgroundSelf-citationShigemoto, R., Kinoshita, A., Wada, E., Nomura, S., Ohishi, H., Takada, M., Flor, P. J., Neki, A., Abe, T., Nakanishi, S., et al. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-19-07503.1997 · Cited by 1,116
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Metabotropic glutamate receptors: electrophysiological properties and role in plasticity
Anwyl, R. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00050-2 · Cited by 780
Schoepp, D. D. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29296-x · Cited by 690
Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression.
Newport, D. J., Carpenter, L. L., McDonald, W. M., Potash, J. B., Tohen, M., Nemeroff, C. B., & The APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15040465 · Cited by 598
Petralia, R. S., Wang, Y.-X., Niedzielski, A. S., & Wenthold, R. J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00533-1 · Cited by 579
Singh, J. B., Fedgchin, M., Daly, E. J., De Boer, P., Cooper, K., Lim, P., Pinter, C., Murrough, J. W., Sanacora, G., Shelton, R. C., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16010037 · Cited by 525
Ohishi, H., Shigemoto, R., Nakanishi, S., & Mizuno, N. (1993) · Journal of Comparative Neurology · doi:10.1002/cne.903350209 · Cited by 512
A Randomized Controlled Trial of Intranasal Ketamine in Major Depressive Disorder
Lapidus, K. A. B., Levitch, C. F., Perez, A. M., Brallier, J. W., Parides, M. K., Soleimani, L., Feder, A., Iosifescu, D. V., Charney, D. S., & Murrough, J. W. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.03.026 · Cited by 480
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0256-5 · Cited by 433
Lorrain, D. S., Baccei, C. S., Bristow, L. J., Anderson, J. J., & Varney, M. A. (2003) · Neuroscience · doi:10.1016/s0306-4522(02)00652-8 · Cited by 432
BDNF release is required for the behavioral actions of ketamine
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., & Duman, R. S. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu033 · Cited by 368
Gamma oscillations as a biomarker for major depression: an emerging topic
Fitzgerald, P. J., & Watson, B. O. (2018) · Translational Psychiatry · doi:10.1038/s41398-018-0239-y · Cited by 366
Koike, H., Iijima, M., & Chaki, S. (2011) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.05.035 · Cited by 346
Monn, J. A., Valli, M. J., Massey, S. M., Hansen, M. M., Kress, T. J., Wepsiec, J. P., Harkness, A. R., Grutsch, Wright, R. A., Johnson, B. G., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980616n · Cited by 293
Acute suppression of spontaneous neurotransmission drives synaptic potentiation
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L. M., & Kavalali, E. T. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4998-12.2013 · Cited by 283
An excitatory synapse hypothesis of depression
Thompson, S. M., Kallarackal, A. J., Kvarta, M. D., Van Dyke, A. M., LeGates, T. A., & Cai, X. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2015.03.003 · Cited by 265 · cited 2×
“High-frequency oscillations in vivo have parallels to many forms of activity-dependent plasticity, such as long-term potentiation, in which high-frequency stimuli induce sustained strengthening of excitatory synapses via an enhanced synchrony between limbicconnected brain regions, likely necessary for antidepressant b…”
BackgroundSynaptic Mechanisms Underlying Rapid Antidepressant Action of Ketamine
Kavalali, E. T., & Monteggia, L. M. (2012) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.12040531 · Cited by 258
Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects
Nugent, A. C., Ballard, E. D., Gould, T. D., Park, L. T., Moaddel, R., Brutsche, N. E., & Zarate, C. A. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0028-2 · Cited by 250 · cited 1×
“In agreement, ketamine-induced increases in gamma power have been recently associated with better antidepressant responses in patients treated for depression (97).”
BackgroundSelf-citationSanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236 · cited 1×
“Results from human studies reveal that an antidepressant dose of ketamine induces an acute enhancement of the power (amplitude) of qEEG oscillations within the 30- to 80-Hz gamma range in the parietal (88), cingulate (88), and cerebral (89) as well as general cortical brain areas (90).”
BackgroundMuthukumaraswamy, S. D., Shaw, A. D., Jackson, L. E., Hall, J., Moran, R., & Saxena, N. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0903-15.2015 · Cited by 234
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219 · cited 1×
“Antidepressant-relevant actions of ketamine and (2R,6R)HNK converge on a glutamate-associated enhancement of neuronal activity in mood-regulating synapses, which are proposed to both initiate and sustain their effects (13, 31, 32).”
BackgroundMiller, O. H., Moran, J. T., & Hall, B. J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.028 · Cited by 200
Fukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188
Effects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180
Moaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176
Self-citationKoike, H., & Chaki, S. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.065 · Cited by 175
Convergent Mechanisms Underlying Rapid Antidepressant Action
Zanos, P., Thompson, S. M., Duman, R. S., Zarate, C. A., & Gould, T. D. (2018) · CNS Drugs · doi:10.1007/s40263-018-0492-x · Cited by 171 · cited 1×
“Glutamate-dependent amplification of neuronal activity via activation of synaptic AMPARs has been broadly hypothesized to underlie the antidepressant actions of ketamine and other putative rapid-acting antidepressants, including (2R,6R)-HNK and mGlu2/3 receptor antagonists (52).”
BackgroundSelf-citationFarber, N. B., Newcomer, J. W., & Olney, J. W. (1998) · Progress in brain research · doi:10.1016/s0079-6123(08)60453-7 · Cited by 169
mTOR activation is required for the antidepressant effects of mGluR2/3 blockade
Dwyer, J. M., Lepack, A. E., & Duman, R. S. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001702 · Cited by 169
A Role for cAMP in Long-Term Depression at Hippocampal Mossy Fiber Synapses
Tzounopoulos, T., Janz, R., Südhof, T. C., Nicoll, R. A., & Malenka, R. C. (1998) · Neuron · doi:10.1016/s0896-6273(00)80599-1 · Cited by 167
Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1816071116 · Cited by 158
Self-citationCavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Molecular and Cellular Mechanisms of Rapid-Acting Antidepressants Ketamine and Scopolamine
Wohleb, E. S., Gerhard, D., Thomas, A., & Duman, R. S. (2017) · Current Neuropharmacology · doi:10.2174/1570159x14666160309114549 · Cited by 148
Rivolta, D., Heidegger, T., Scheller, B., Sauer, A., Schaum, M., Birkner, K., Singer, W., Wibral, M., & Uhlhaas, P. J. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv051 · Cited by 147
Homayoun, H., Jackson, M. E., & Moghaddam, B. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00875.2004 · Cited by 137
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133 · cited 1×
“High-frequency oscillations in vivo have parallels to many forms of activity-dependent plasticity, such as long-term potentiation, in which high-frequency stimuli induce sustained strengthening of excitatory synapses via an enhanced synchrony between limbicconnected brain regions, likely necessary for antidepressant b…”
BackgroundSelf-citationThe STAR*D Trial: Revealing the Need for Better Treatments
Insel, T. R., & Wang, P. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1466 · Cited by 131
Pham, T. H., Defaix, C., Xu, X., Deng, S.-X., Fabresse, N., Alvarez, J.-C., Landry, D. W., Brachman, R. A., Denny, C. A., & Gardier, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.020 · Cited by 131
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0083-8 · Cited by 123
Ketamine amplifies induced gamma frequency oscillations in the human cerebral cortex
Shaw, A. D., Saxena, N., E. Jackson, L., Hall, J. E., Singh, K. D., & Muthukumaraswamy, S. D. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.012 · Cited by 122 · cited 1×
“Results from human studies reveal that an antidepressant dose of ketamine induces an acute enhancement of the power (amplitude) of qEEG oscillations within the 30- to 80-Hz gamma range in the parietal (88), cingulate (88), and cerebral (89) as well as general cortical brain areas (90).”
BackgroundZanos, P., Piantadosi, S. C., Wu, H., Pribut, H. J., Dell, M. J., Can, A., Snodgrass, H. R., Zarate, C. A., Schwarcz, R. M., & Gould, T. D. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.225664 · Cited by 121
Self-citationLinden, A.-M., Shannon, H. E., Baez, M., Yu, J., Koester, A., & Schoepp, D. D. (2004) · Psychopharmacology · doi:10.1007/s00213-004-2098-x · Cited by 118
Yao, N., Skiteva, O., Zhang, X., Svenningsson, P., & Chergui, K. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.239 · Cited by 118
Gozzi, A., Large, C. H., Schwarz, A. J., Bertani, S., Crestan, V., & Bifone, A. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301547 · Cited by 116
Dong, C., Zhang, J.-C., Yao, W., Ren, Q., Ma, M., Yang, C., Chaki, S., & Hashimoto, K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw089 · Cited by 116
Zhang, L., Shirayama, Y., Iyo, M., & Hashimoto, K. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301313 · Cited by 110
Jones, N. C., Reddy, M., Anderson, P., Salzberg, M. R., O'Brien, T. J., & Pinault, D. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000848 · Cited by 107
Fukumoto, K., Iijima, M., & Chaki, S. (2014) · Psychopharmacology · doi:10.1007/s00213-013-3378-0 · Cited by 107
Zanos, P., Nelson, M. E., Highland, J. N., Krimmel, S. R., Georgiou, P., Gould, T. D., & Thompson, S. M. (2017) · eNeuro · doi:10.1523/eneuro.0285-16.2017 · Cited by 106
Self-citationWitkin, J. M., Monn, J. A., Schoepp, D. D., Li, X., Overshiner, C., Mitchell, S. N., Carter, G., Johnson, B., Rasmussen, K., & Rorick-Kehn, L. M. (2016) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.233627 · Cited by 105
Chou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104
Ago, Y., Yano, K., Araki, R., Hiramatsu, N., Kita, Y., Kawasaki, T., Onoe, H., Chaki, S., Nakazato, A., Hashimoto, H., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.09.008 · Cited by 99
Koike, H., Fukumoto, K., Iijima, M., & Chaki, S. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.10.023 · Cited by 99
Zhang, K., Xu, T., Yuan, Z., Wei, Z., Yamaki, V. N., Huang, M., Huganir, R. L., & Cai, X. (2016) · Science Signaling · doi:10.1126/scisignal.aai7884 · Cited by 98
Uncoupling DAPK1 from NMDA receptor GluN2B subunit exerts rapid antidepressant-like effects
Li, S.-X., Han, Y., Xu, L.-Z., Yuan, K., Zhang, R.-X., Sun, C.-Y., Xu, D.-F., Yuan, M., Deng, J.-H., Meng, S.-Q., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.85 · Cited by 98
Kocsis, B., Brown, R. E., McCarley, R. W., & Hajos, M. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12081 · Cited by 92
Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83
Self-citationDwyer, J. M., Lepack, A. E., & Duman, R. S. (2013) · Journal of Molecular Psychiatry · doi:10.1186/2049-9256-1-15 · Cited by 81
Chen, Y.-L., Huang, C.-C., & Hsu, K.-S. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-11-03705.2001 · Cited by 80
Irifune, M., Shimizu, T., Nomoto, M., & Fukuda, T. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)00379-w · Cited by 78
mGlu2/3 Receptor Antagonists as Novel Antidepressants
Chaki, S. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.03.008 · Cited by 73
Imre, G., Salomons, A. R., Jongsma, M. E., Fokkema, D. S., den Boer, J. A., & Horst, G. J. T. (2006) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2006.05.021 · Cited by 66
Grent-‘t-Jong, T., Rivolta, D., Gross, J., Gajwani, R., Lawrie, S. M., Schwannauer, M., Heidegger, T., Wibral, M., Singer, W., Sauer, A., et al. (2018) · Brain · doi:10.1093/brain/awy175 · Cited by 66
Chin, C., Upadhyay, J., Marek, G. J., Baker, S. J., Zhang, M., Mezler, M., Fox, G. B., & Day, M. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173880 · Cited by 63
Highland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62
Self-citationKew, J. N. C., Pflimlin, M., Kemp, J. A., & Mutel, V. (2002) · Neuropharmacology · doi:10.1016/s0028-3908(02)00084-9 · Cited by 57
Mehta, M. A., Schmechtig, A., Kotoula, V., McColm, J., Jackson, K. A., Brittain, C., Tauscher‐Wisniewski, S., Kinon, B. J., Morrison, P. D., Pollak, T. A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4877-9 · Cited by 47
Podkowa, K., Pochwat, B., Brański, P., Pilc, A., & Pałucha-Poniewiera, A. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4325-7 · Cited by 43
Witkin, J. M., Mitchell, S. N., Wafford, K. A., Carter, G., Gilmour, G., Li, J., Eastwood, B. J., Overshiner, C. D., Li, X., Rorick‐Kehn, L. M., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.238121 · Cited by 42
Collado, I., Pedregal, C., Mazón, Á., Espinosa, J. F., Blanco‐Urgoiti, J., Schoepp, D. D., Wright, R. A., Johnson, B. G., & Kingston, A. E. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm0110486 · Cited by 39
Dedeurwaerdere, S., Wintmolders, C., Straetemans, R., Pemberton, D. J., & Langlois, X. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2052-z · Cited by 38
Torrisi, S. A., Salomone, S., Geraci, F., Caraci, F., Bucolo, C., Drago, F., & Leggio, G. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00710 · Cited by 37
Collo, G., Cavalleri, L., Chiamulera, C., & Merlo Pich, E. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001131 · Cited by 37
Hiyoshi, T., Marumo, T., Hikichi, H., Tomishima, Y., Urabe, H., Tamita, T., Iida, I., Yasuhara, A., Karasawa, J.-I., & Chaki, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.218651 · Cited by 36
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2017) · Nature · doi:10.1038/nature22085 · Cited by 34
Self-citationEffects of aberrant gamma frequency oscillations on prepulse inhibition
Jones, N. C., Anderson, P., Rind, G., Sullivan, C., van den Buuse, M., & O'Brien, T. J. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000492 · Cited by 33
Ahnaou, A., Ver Donck, L., & Drinkenburg, W. H. I. M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.003 · Cited by 31 · cited 1×
“In line with our findings, a previous study also showed increases in the gamma power range (30–49 Hz) 2–4 h (but not 1 h) after functional inhibition of the mGlu2/3 receptor in rats (98); however, that study restricted qEEG analyses to frequencies between 1 and 49 Hz, thus excluding gamma frequencies between 50 and 80…”
ResultAgnieszka, P.-P., Karolina, P., & Andrzej, P. (2019) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000471 · Cited by 31
Gleason, S. D., Li, X., Smith, I. A., Ephlin, J. D., Wang, X.-S., Heinz, B. A., Carter, J. H., Baez, M., Yu, J., Bender, D. M., et al. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113129990079 · Cited by 29
What’s the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise?
Abdallah, C. G. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.01.002 · Cited by 25
Hikichi, H., Hiyoshi, T., Marumo, T., Tomishima, Y., Kaku, A., Iida, I., Urabe, H., Tamita, T., Yasuhara, A., Karasawa, J.-I., et al. (2015) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2015.02.004 · Cited by 24
Hiyoshi, T., Hikichi, H., Karasawa, J.-I., & Chaki, S. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.03.025 · Cited by 24
Fujáková, M., Páleníček, T., Brunovský, M., Gorman, I., Tylš, F., Kubešová, A., Řípová, D., Krajča, V., & Horáček, J. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.03.001 · Cited by 23
Refsgaard, L. K., Pickering, D. S., & Andreasen, J. T. (2016) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000266 · Cited by 22
Fava, M., Freeman, M. P., Flynn, M., Judge, H., Hoeppner, B. B., Cusin, C., Ionescu, D. F., Mathew, S. J., Chang, L. C., Iosifescu, D. V., et al. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0311-2 · Cited by 20
Imre, G., Fokkema, D. S., & Horst, G. J. T. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.06.037 · Cited by 18
Joffe, M. E., & Conn, P. J. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0192-8 · Cited by 17
Wyckhuys, T., Wyffels, L., Langlois, X., Schmidt, M. E., Stroobants, S. G., & Staelens, S. G. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.213959 · Cited by 16
Narimatsu, E., Kawamata, Y., Kawamata, M., Fujimura, N., & Namiki, A. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03375-9 · Cited by 14
Talbot, J. N., Geffert, L. M., Jorvig, J. E., Goldstein, R. I., Nielsen, C. L., Wolters, N. E., Amos, M. E., Munro, C. A., Dallman, E., Mereu, M., et al. (2016) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2016.08.007 · Cited by 14
Thompson, H., Neale, S. A., & Salt, T. E. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.06.019 · Cited by 13
Mele, A., Oliverio, A., & Castellano, C. (1995) · Psychopharmacology · doi:10.1007/bf02246081 · Cited by 13
Umbricht, D., Niggli, M., Ducray, P. S., Deptula, D., Moore, R., Grünbauer, W., Boak, L. M., Gatti, S., & da Fontoura, P. P. (2015) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(15)30600-3 · Cited by 9
Park, M. H., Choi, M., Kim, Y.-S., & Son, H. (2018) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2018.22.2.155 · Cited by 1
Cited by
Duman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
“Rather (2R,6R)-HNK is thought to act via an mGlu2 receptor-like presynaptic mechanism to increase glutamate release (Riggs et al., 2019; Zanos et al., 2019).”
BackgroundNeuroplasticity as a convergent mechanism of ketamine and classical psychedelics
Aleksandrova, L. R., & Phillips, A. G. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.08.003 · Cited by 276
Ketamine: A tale of two enantiomers
Jelen, L. A., Young, A. H., & Stone, J. M. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959644 · Cited by 246
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109836 · Cited by 224
“Immobility was defined as passive floating with no additional activity except that needed to maintain the head of the animal above the water level (Zanos et al., 2019).”
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Metadata
- Authors
- Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., & Gould, T. D.
- Affiliations
- University of Maryland, Baltimore (US)
- National Institutes of Health (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-03-13
- Volume
- 116
- Issue
- 13
- Pages
- 6441-6450
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6442605
- OpenAlex
- W2922048335
- Cited by
- 152
- References
- 110
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 12 · 2023: 22 · 2022: 27 · 2021: 25 · 2020: 24 · 2019: 11
- FWCI
- 13.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Brain and Behavior Research Foundation (26826)
- HHS | NIH | National Institute of Mental Health (MH107615)
- U.S. Department of Veterans Affairs (1I01BX004062)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- (2R,6R)-hydroxynorketamine, ketamine metabolites, mGlu2 receptor, metabotropic glutamate receptors, antidepressant effects, rapid-acting antidepressants, depression, treatment-resistant depression, ketamine
- MeSH terms
- Amino Acids, Animals, Antidepressive Agents, Behavior, Animal, Depression, Disease Models, Animal, Drug Resistance, Female, Fever, Ketamine, Male, Mice, Inbred C57BL, Receptors, N-Methyl-D-Aspartate, Receptors, Metabotropic Glutamate, Mice, Knockout, Bridged Bicyclo Compounds, Heterocyclic, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.